Tilray Brands (TLRY) Aandelenoverzicht
Tilray Brands, Inc. is een lifestylebedrijf dat zich bezighoudt met onderzoek, kweek, verwerking en distributie van medische cannabisproducten in Canada, de Verenigde Staten, Europa, het Midden-Oosten, Afrika en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
TLRY Community Fair Values
Create NarrativeSee what 164 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tilray Brands, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.43 |
| 52 Week Hoogtepunt | US$23.20 |
| 52 Week Laag | US$4.20 |
| Bèta | 1.87 |
| 1 maand verandering | -19.31% |
| 3 maanden verandering | -32.37% |
| 1 Jaar Verandering | -8.70% |
| 3 jaar verandering | -72.99% |
| 5 jaar verandering | -97.27% |
| Verandering sinds IPO | -97.25% |
Recent nieuws en updates
Narratiefupdate • Jun 24
TLRY: Partial Cannabis Rescheduling And Beverage Partnerships Will Improve Future Cash Flow Visibility
Analysts recently trimmed their average 12 month price target for Tilray Brands to about $6.50 from roughly $9.00. This reflects updated assumptions for slower revenue growth, slightly lower profit margins, a higher discount rate and a reduced future P/E multiple, even as some research cites potential benefits from partial cannabis re scheduling.Seeking Alpha • Jun 19
Tilray Looks Cheap On The Surface, But Shareholders Still Need Proof
Summary Tilray Brands is rated Hold, trading at a discounted 0.5–0.6x P/S due to persistent unprofitability and dilution risk. Despite $1B+ pro forma revenue post-BrewDog, TLRY's low margins and negative free cash flow undermine its investment case. Management's history of value-destructive acquisitions and frequent equity dilution justifies the steep valuation discount. I require clear evidence of sustainable cash flow before considering TLRY a buy; for now, it remains a watchlist candidate. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Jun 24
TLRY: Partial Cannabis Rescheduling And Beverage Partnerships Will Improve Future Cash Flow Visibility
Analysts recently trimmed their average 12 month price target for Tilray Brands to about $6.50 from roughly $9.00. This reflects updated assumptions for slower revenue growth, slightly lower profit margins, a higher discount rate and a reduced future P/E multiple, even as some research cites potential benefits from partial cannabis re scheduling.Seeking Alpha • Jun 19
Tilray Looks Cheap On The Surface, But Shareholders Still Need Proof
Summary Tilray Brands is rated Hold, trading at a discounted 0.5–0.6x P/S due to persistent unprofitability and dilution risk. Despite $1B+ pro forma revenue post-BrewDog, TLRY's low margins and negative free cash flow undermine its investment case. Management's history of value-destructive acquisitions and frequent equity dilution justifies the steep valuation discount. I require clear evidence of sustainable cash flow before considering TLRY a buy; for now, it remains a watchlist candidate. Read the full article on Seeking Alpha
Narratiefupdate • Jun 06
TLRY: Cannabis Rescheduling And Margin Outlook Will Drive Future Upside Potential
Tilray Brands' consensus analyst price target has been reset lower by roughly $2 to $3 per share as analysts factor in updated cannabis re-scheduling expectations and revised profit margin and future P/E assumptions following recent firm-level target cuts and one upgrade. Analyst Commentary Recent Street research on Tilray Brands shows a mix of optimism around potential regulatory shifts and caution around profit expectations and valuation multiples.Narratiefupdate • May 17
TLRY: BrewDog Deal And Cannabis Rescheduling Will Shape Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands by a few dollars to reflect updated assumptions around discount rates, profit margins and future P/E multiples, even as some highlight potential benefits from partial cannabis rescheduling and recent acquisitions. Analyst Commentary Bullish Takeaways Bullish analysts view the partial cannabis rescheduling order as extremely favorable, seeing scope for improved sector sentiment and potential support for valuation multiples if regulatory risk is perceived as lower.Narratiefupdate • May 02
TLRY: BrewDog Acquisition And Cannabis Rescheduling Will Drive Future Upside
Analysts have cut their average price target on Tilray Brands to about $10.04 from $16.17, reflecting updated assumptions on discount rates, revenue growth, profit margins, and a reset future P/E following recent research that includes target reductions tied to the BrewDog asset acquisition and evolving views on potential U.S. cannabis rescheduling. Analyst Commentary Recent research on Tilray Brands highlights a mix of optimism around regulatory developments and caution around execution risks, especially following the BrewDog asset acquisition and a series of price target resets.
Narratiefupdate • Apr 18
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Narratiefupdate • Apr 04
TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility
Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.Narratiefupdate • Mar 20
TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility
Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.Narratiefupdate • Mar 05
TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility
Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.Narratiefupdate • Feb 19
TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility
Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.Narratiefupdate • Feb 05
TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility
Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.Narratiefupdate • Jan 21
TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility
Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.Analyseartikel • Jan 16
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop
To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 30% in the...Narratiefupdate • Jan 06
TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles
Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.Narratiefupdate • Dec 20
TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances
Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.Narratiefupdate • Dec 06
TLRY: Reverse Split And Medical Expansion Will Drive Future Upside
Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).Analyseartikel • Nov 24
Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
The Tilray Brands, Inc. ( NASDAQ:TLRY ) share price has fared very poorly over the last month, falling by a substantial...Narratiefupdate • Nov 22
TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities
Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.Narratiefupdate • Nov 07
TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access
Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.Narratiefupdate • Oct 23
Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets
Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.Narratiefupdate • Oct 09
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.Analyseartikel • Oct 03
Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have continued their recent momentum with a 29% gain in the last month...Narratiefupdate • Aug 26
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.Analyseartikel • Aug 18
Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have been powering on, with a gain of 66% in...Analyseartikel • Jul 04
Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth
Tilray Brands, Inc. ( NASDAQ:TLRY ) shareholders are no doubt pleased to see that the share price has bounced 35% in...
Nieuw narratief • May 04
Integrated Operations Will Extend European And US THC Beverage Markets
Strategic initiatives focusing on margin improvements and global expansion efforts could significantly boost profitability and revenue growth.Seeking Alpha • Apr 28
Tilray Brands Could Bounce Big
Summary Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Despite revenue and EBITDA misses, Tilray's valuation is attractive, trading at 6.85X projected FY27 adjusted EBITDA, suggesting potential gains of up to 77%. Risks include NASDAQ delisting and integration challenges from numerous acquisitions, but maintaining the NASDAQ listing is crucial. I remain optimistic due to Tilray's technical indicators and valuation, despite concerns about its cannabis operations and other business units. Read the full article on Seeking AlphaRendement voor aandeelhouders
| TLRY | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -3.5% | 4.7% | 1.6% |
| 1Y | -8.7% | 45.4% | 21.1% |
Rendement versus industrie: TLRY presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 45.4 % opleverde.
Rendement versus markt: TLRY presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 21.1 % opleverde.
Prijsvolatiliteit
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: TLRY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van TLRY is het afgelopen jaar gedaald van 18% naar 8%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 2,842 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., een lifestyle consumentenproductenbedrijf, houdt zich bezig met onderzoek, kweek, verwerking en distributie van medische cannabisproducten in Canada, de Verenigde Staten, Europa, het Midden-Oosten, Afrika en internationaal. Het bedrijf is actief in vier segmenten: Drank, Cannabis, Distributie en Wellness. Het bedrijf biedt ook cannabisproducten voor medisch gebruik en gebruik door volwassenen, verkoopt en distribueert farmaceutische en welzijnsproducten en produceert, verkoopt en verkoopt drankproducten en voedingsproducten op basis van hennep.
Tilray Brands, Inc. Samenvatting
| TLRY fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$535.58m |
| Inkomsten(TTM) | -US$1.34b |
| Inkomsten(TTM) | US$858.28m |
0.6x
P/S-verhouding-0.4x
Koers/WinstverhoudingIs TLRY overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TLRY resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$858.28m |
| Kosten van inkomsten | US$620.72m |
| Brutowinst | US$237.55m |
| Overige uitgaven | US$1.58b |
| Inkomsten | -US$1.34b |
Laatst gerapporteerde inkomsten
Feb 28, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -11.27 |
| Brutomarge | 27.68% |
| Nettowinstmarge | -156.67% |
| Schuld/Eigen Vermogen Verhouding | 16.4% |
Hoe presteerde TLRY op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/01 21:04 |
| Aandelenkoers aan het einde van de dag | 2026/07/01 00:00 |
| Inkomsten | 2026/02/28 |
| Jaarlijkse inkomsten | 2025/05/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Tilray Brands, Inc. wordt gevolgd door 27 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |